Information  X 
Enter a valid email address

EPIC/TIDM matching '0RQJ'

Date
Time Source
Company
Announcement
31 Mar 2020 7:00 am GNW Factsheet Saniona AB (0RQJ) Saniona changes date for Annual General Meeting and updates financial calendar
26 Mar 2020 7:00 am GNW Factsheet Saniona AB (0RQJ) Saniona enters into second collaboration agreement with Boehringer Ingelheim in schizophrenia
24 Mar 2020 7:00 am GNW Factsheet Saniona AB (0RQJ) Saniona Announces Management Transition to Support Strategic Transformation
18 Mar 2020 3:10 pm GNW Factsheet Saniona AB (0RQJ) Saniona completes its six months double blind Phase 2a trial of Tesomet in hypothalamic obesity
11 Mar 2020 1:30 pm GNW Factsheet Saniona AB (0RQJ) Saniona’s announces last day of trading in BTU and first day of trading in warrants of series TO 1, TO 2 and TO 3
04 Mar 2020 5:20 pm GNW Factsheet Saniona AB (0RQJ) Saniona’s rights issue of free-of-payment units is oversubscribed
19 Feb 2020 4:00 pm GNW Factsheet Saniona AB (0RQJ) Saniona publishes supplementary prospectus
18 Feb 2020 4:35 pm GNW Factsheet Saniona AB (0RQJ) Saniona announces Chief Financial Officer Thomas Feldthus will be departing the company
  7:00 am GNW Factsheet Saniona AB (0RQJ) Saniona co-founds new migraine therapy company Cephagenix
14 Feb 2020 2:55 pm GNW Factsheet Saniona AB (0RQJ) Correction regarding ISIN code for BTU in prospectus
  8:40 am GNW Factsheet Saniona AB (0RQJ) Saniona publishes prospectus relating to the rights issue of units
07 Feb 2020 10:35 am GNW Factsheet Saniona AB (0RQJ) Bulletin from the extraordinary general meeting on February 7, 2020 in Saniona AB
  7:00 am GNW Factsheet Saniona AB (0RQJ) Saniona publishes its year-end report for 2019
31 Jan 2020 7:00 am GNW Factsheet Saniona AB (0RQJ) Change in number of shares and votes in Saniona AB (publ)
10 Jan 2020 7:10 am GNW Factsheet Saniona AB (0RQJ) Notice of extraordinary general meeting in Saniona AB
  7:00 am GNW Factsheet Saniona AB (0RQJ) Saniona completes private placement of SEK 25 million and proposes financing of up to SEK 158 million
07 Jan 2020 7:00 am GNW Factsheet Saniona AB (0RQJ) Saniona appoints CNS & rare disease veteran Rami Levin as President and Chief Executive Officer
23 Dec 2019 12:10 pm GNW Factsheet Saniona AB (0RQJ) Saniona’s partner Medix submits new drug application in Mexico for tesofensine in obesity
29 Nov 2019 7:00 am GNW Factsheet Saniona AB (0RQJ) Change in number of shares and votes in Saniona AB (publ)
27 Nov 2019 7:00 am GNW Factsheet Saniona AB (0RQJ) Saniona AB’s Nomination Committee for the Annual General Meeting 2020
13 Nov 2019 7:00 am GNW Factsheet Saniona AB (0RQJ) Saniona publishes its interim report for the third quarter 2019
11 Nov 2019 7:00 am GNW Factsheet Saniona AB (0RQJ) Saniona completes patient recruitment in Phase 2a hypothalamic obesity study
30 Sep 2019 7:00 am GNW Factsheet Saniona AB (0RQJ) Change in number of shares and votes in Saniona AB (publ)
18 Sep 2019 7:00 am GNW Factsheet Saniona AB (0RQJ) Saniona reports positive Tesomet Phase 2a clinical results in adolescent patients with Prader-Willi syndrome
21 Aug 2019 7:00 am GNW Factsheet Saniona AB (0RQJ) Saniona publishes its interim report for the second quarter 2019
31 Jul 2019 7:00 am GNW Factsheet Saniona AB (0RQJ) Change in number of shares and votes in Saniona AB (publ)
22 Jul 2019 7:00 am GNW Factsheet Saniona AB (0RQJ) Saniona selects highly promising preclinical candidate with broad potential in autoimmune disorders
28 Jun 2019 3:05 pm GNW Factsheet Saniona AB (0RQJ) Saniona’s rights issue completed
  7:00 am GNW Factsheet Saniona AB (0RQJ) Change in number of shares and votes in Saniona AB (publ)
07 Jun 2019 9:25 am GNW Factsheet Saniona AB (0RQJ) Saniona publishes prospectus relating to the rights issue
29 May 2019 5:00 pm GNW Factsheet Saniona AB (0RQJ) BULLETIN FROM THE ANNUAL SHAREHOLDERS’ MEETING ON MAY 29, 2019 IN SANIONA AB (PUBL)
  7:00 am GNW Factsheet Saniona AB (0RQJ) Saniona publishes its interim report for the first quarter 2019
28 May 2019 4:45 pm GNW Factsheet Saniona AB (0RQJ) Saniona announces rights issue of SEK 78 million underwritten up to 85 percent
13 May 2019 7:45 am GNW Factsheet Saniona AB (0RQJ) Saniona forms PWS Scientific Advisory Board and provides update on ongoing study
30 Apr 2019 9:15 am GNW Factsheet Saniona AB (0RQJ) Saniona publishes the Annual Report for 2018
26 Apr 2019 7:30 am GNW Factsheet Saniona AB (0RQJ) Notice of annual shareholders’ meeting in Saniona AB
  7:00 am GNW Factsheet Saniona AB (0RQJ) The Nomination Committee of Saniona Proposes Election of One Additional Member of the Board of Directors
29 Mar 2019 9:30 am GNW Factsheet Saniona AB (0RQJ) Change in number of shares and votes in Saniona AB (publ)
11 Mar 2019 7:00 am GNW Factsheet Saniona AB (0RQJ) Saniona initiates Phase 2a Tesomet clinical study in hypothalamic obesity patients
21 Feb 2019 7:00 am GNW Factsheet Saniona AB (0RQJ) Saniona publishes its year-end report for 2019
18 Feb 2019 7:00 am GNW Factsheet Saniona AB (0RQJ) Saniona’s SAN711 selected for clinical studies in itching and pain
23 Jan 2019 7:00 am GNW Factsheet Saniona AB (0RQJ) Saniona reports UPenn to continue cocaine addiction study with NS2359 at higher dose after blinded interim analysis
07 Jan 2019 7:00 am GNW Factsheet Saniona AB (0RQJ) Saniona completes treatment in Phase 2a Prader-Willi syndrome trial and initiates open label extension study
28 Dec 2018 8:45 am GNW Factsheet Saniona AB (0RQJ) Change in number of shares and votes in Saniona AB (publ)
17 Dec 2018 12:00 pm GNW Factsheet Saniona AB (0RQJ) Saniona’s tesofensine meets primary and secondary endpoints in Phase 3 obesity registration trial
13 Dec 2018 7:00 am GNW Factsheet Saniona AB (0RQJ) Saniona AB’s Nomination Committee for the Annual General Meeting 2019
15 Nov 2018 11:00 am GNW Factsheet Saniona AB (0RQJ) Saniona’s partner Cadent Therapeutics initiates Phase 2 for CAD-1883 and secures USD 40 million financing
14 Nov 2018 7:00 am GNW Factsheet Saniona AB (0RQJ) Saniona publishes its interim report for the third quarter 2018
08 Nov 2018 7:30 am GNW Factsheet Saniona AB (0RQJ) Saniona signs option agreement with Initiator Pharma
04 Oct 2018 7:00 am GNW Factsheet Saniona AB (0RQJ) Saniona Completes Planned Patient Recruitment for Second Part of Phase 2a Study for Tesomet in Prader-Willi Syndrome
01 Oct 2018 1:00 pm GNW Factsheet Saniona AB (0RQJ) Saniona’s spin-out, Scandion Oncology obtains approval for listing at Spotlight Stock Market
28 Sep 2018 10:00 am GNW Factsheet Saniona AB (0RQJ) Change in number of shares and votes in Saniona AB (publ)
22 Aug 2018 7:00 am GNW Factsheet Saniona AB (0RQJ) Saniona publishes its interim report for the second quarter 2018
12 Jul 2018 7:00 am GNW Factsheet Saniona AB (0RQJ) Saniona receives milestone payment from Boehringer Ingelheim
29 Jun 2018 12:15 pm GNW Factsheet Saniona AB (0RQJ) Change in number of shares and votes in Saniona AB (publ)
28 Jun 2018 9:40 am GNW Factsheet Saniona AB (0RQJ) Saniona awarded grant of SEK 1.4 million for Kv7 program
11 Jun 2018 7:00 am GNW Factsheet Saniona AB (0RQJ) Saniona plans Phase 2a study for treatment of Hypothalamic Obesity
05 Jun 2018 7:00 am GNW Factsheet Saniona AB (0RQJ) Saniona reports positive results from preclinical studies for Tesomet opening op for long-term clinical studies
29 May 2018 11:25 am GNW Factsheet Saniona AB (0RQJ) Saniona reports positive results from Phase 1 study with new Tesomet tablet


Company Announcements Archive »

 
Headlines
Top categories

07-Apr-2020 04:50 PM

Broker Forecast - Jefferies International issues a broker note on John Wood Group PLC

Jefferies International today reaffirms its hold investment rating on John Wood Group PLC (LON:WG.) and cut its price target to 200p (from 350p). Sto ...

Company finder
Forthcoming announcements

a d v e r t i s e m e n t